Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer

被引：328

作者：

Dieci, Maria Vittoria ^{[1
,2
]}

Radosevic-Robin, Nina ^{[3
,4
]}

Fineberg, Susan ^{[5
,6
]}

van den Eynden, Gert ^{[7
,8
]}

Ternes, Nils ^{[9
,10
]}

Penault-Llorca, Frederique ^{[3
,4
,11
]}

Pruneri, Giancarlo ^{[12
,13
]}

D'Alfonso, Timothy M. ^{[14
]}

Demaria, Sandra ^{[15
]}

Castaneda, Carlos ^{[16
]}

Sanchez, Joselyn ^{[16
]}

Badve, Sunil ^{[17
]}

Michiels, Stefan ^{[9
,10
]}

Bossuyt, Veerle ^{[18
]}

Rojo, Federico ^{[19
]}

Singh, Baljit ^{[20
]}

Nielsen, Torsten ^{[21
]}

Viale, Giuseppe ^{[22
]}

Kim, Seong-Rim ^{[23
]}

Hewitt, Stephen ^{[24
]}

Wienert, Stephan ^{[25
]}

Loibl, Sybille ^{[26
]}

Rimm, David ^{[18
]}

Symmans, Fraser ^{[27
]}

Denkert, Carsten ^{[28
]}

Adams, Sylvia ^{[29
]}

Loi, Sherene ^{[30
]}

Salgado, Roberto ^{[31
,32
,33
]}

机构：

[1] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy

[2] IRCCS, Med Oncol 2, Veneto Inst Oncol IOV, Padua, Italy

[3] Jean Perrin Comprehens Canc Ctr, Dept Surg Pathol & Biopathol, Clermont Ferrand, France

[4] Univ Auvergne U1240, INSERM, Clermont Ferrand, France

[5] Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA

[6] Albert Einstein Coll Med, Bronx, NY 10467 USA

[7] Univ Libre Bruxelles, Inst Jules Bordet, Mol Immunol Unit, Brussels, Belgium

[8] GZA Ziekenhuizen, Dept Pathol, Antwerp, Belgium

[9] Serv Biostat & Epidemiol, Gustave Roussy, B2 M,RdC,114 Rue Edouard Vaillant, F-94805 Villejuif, France

[10] Univ Paris Sud, Univ Paris Saclay, INSERM, Fac Med UVSQ,CESP, F-94805 Villejuif, France

[11] Univ Auvergne, Sch Med, Clermont Ferrand, France

[12] Fdn IRCCS Ist Nazl Tumori, Div Pathol, Milan, Italy

[13] Univ Milan, Sch Med, Milan, Italy

[14] Weill Cornell Med, Dept Pathol & Lab Med, New York, NY USA

[15] Weill Cornell Med, Dept Radiat Oncol, New York, NY USA

[16] Inst Nacl Enfermedades Neoplas, Dept Res, Lima 15038, Peru

[17] Indiana Univ, Dept Pathol & Lab Med, Indianapolis, IN 46204 USA

[18] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA

[19] UAM, Pathol Dept, Fdn Jimenez Diaz, IIS, Madrid, Spain

[20] Coney Isl Hosp, Dept Pathol, New York, NY USA

[21] Univ British Columbia, Dept Pathol & Lab Med, Genet Pathol Evaluat Ctr, Vancouver, BC, Canada

[22] Univ Milan, Ist Europeo Oncol, Dept Pathol, Milan, Italy

[23] NRG Oncol, Natl Surg Adjuvant Breast & Bowel Project Operat, Pittsburgh, PA USA

[24] NCI, Expt Pathol Lab, Pathol Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA

[25] Dlw Laborsoftware UG Haftungsbeschrankt, Lubben, Germany

[26] German Breast Grp, Neu Isenburg, Germany

[27] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA

[28] Charite Univ Med Berlin, Inst Pathol, Berlin, Germany

[29] NYU, Sch Med, Perlmutter Canc Ctr, New York, NY USA

[30] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia

[31] Peter Mac Callum Canc Ctr, Translat Breast Canc Genom & Therapeut Lab, Melbourne, Vic, Australia

[32] Jules Border Inst, Breast Canc Translat Res Lab, Brussels, Belgium

[33] GZA, Dept Pathol, Antwerp, Belgium

来源：

SEMINARS IN CANCER BIOLOGY | 2018年 / 52卷

关键词：

Tumor-infiltrating lymphocytes; Breast cancer; Neoadjuvant; Residual disease; Ductal carcinoma in situ; Residual cancer burden; PATHOLOGICAL COMPLETE RESPONSE; PREDICTIVE-VALUE; CHEMOTHERAPY; TRASTUZUMAB; SURVIVAL; CARBOPLATIN; BURDEN; DCIS;

D O I：

10.1016/j.semcancer.2017.10.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer is gaining momentum as evidence strengthens the clinical relevance of this immunological biomarker. TILs in the post-neoadjuvant residual disease setting are acquiring increasing importance as a stratifying marker in clinical trials, considering the raising interest on immunotherapeutic strategies after neoadjuvant chemotherapy. TILs in ductal carcinoma in situ, with or without invasive carcinoma, represent an emerging area of clinical breast cancer research. The aim of this report is to update pathologists, clinicians and researchers on TIL assessment in both the post-neoadjuvant residual disease and the ductal carcinoma in situ settings. The International Immuno-Oncology Working Group proposes a method for assessing TILs in these settings, based on the previously published International Guidelines on TIL Assessment in Breast Cancer. In this regard, these recommendations represent a consensus guidance for pathologists, aimed to achieve the highest possible consistency among future studies.

引用

页码：16 / 25

页数：10

共 49 条

[41]

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 [J].

Salgado, R. ;

Denkert, C. ;

Demaria, S. ;

Sirtaine, N. ;

Klauschen, F. ;

Pruneri, G. ;

Wienert, S. ;

Van den Eynden, G. ;

Baehner, F. L. ;

Penault-Llorca, F. ;

Perez, E. A. ;

Thompson, E. A. ;

Symmans, W. F. ;

Richardson, A. L. ;

Brock, J. ;

Criscitiello, C. ;

Bailey, H. ;

Ignatiadis, M. ;

Floris, G. ;

Sparano, J. ;

Kos, Z. ;

Nielsen, T. ;

Rimm, D. L. ;

Allison, K. H. ;

Reis-Filho, J. S. ;

Loibl, S. ;

Sotiriou, C. ;

Viale, G. ;

Badve, S. ;

Adams, S. ;

Willard-Gallo, K. ;

Loi, S. .

ANNALS OF ONCOLOGY, 2015, 26 (02) :259-271

[42]

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab A Secondary Analysis of the NeoALTTO Trial [J].

Salgado, Roberto ;

Denkert, Carsten ;

Campbell, Christine ;

Savas, Peter ;

Nuciforo, Paolo ;

Aura, Claudia ;

de Azambuja, Evandro ;

Eidtmann, Holger ;

Ellis, Catherine E. ;

Baselga, Jose ;

Piccart-Gebhart, Martine J. ;

Michiels, Stefan ;

Bradbury, Ian ;

Sotiriou, Christos ;

Loi, Sherene .

JAMA ONCOLOGY, 2015, 1 (04) :448-455

[43]

Clinical relevance of host immunity in breast cancer: from TILs to the clinic [J].

Savas, Peter ;

Salgado, Roberto ;

Denkert, Carsten ;

Sotiriou, Christos ;

Darcy, Phillip K. ;

Smyth, Mark J. ;

Loi, Sherene .

NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (04) :228-241

[44]

Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes A Systematic Review [J].

Stanton, Sasha E. ;

Adams, Sylvia ;

Disis, Mary L. .

JAMA ONCOLOGY, 2016, 2 (10) :1354-1360

[45]

Measurement of residual breast cancer burden to predict survival after Neoadjuvant chemotherapy [J].

Symmans, W. Fraser ;

Peintinger, Florentia ;

Hatzis, Christos ;

Rajan, Radhika ;

Kuerer, Henry ;

Valero, Vicente ;

Assad, Lina ;

Poniecka, Anna ;

Hennessy, Bryan ;

Green, Marjorie ;

Buzdar, Aman U. ;

Singletary, S. Eva ;

Hortobagyi, Gabriel N. ;

Pusztai, Lajos .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (28) :4414-4422

[46]

Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype [J].

Symmans, W. Fraser ;

Wei, Caimiao ;

Gould, Rebekah ;

Yu, Xian ;

Zhang, Ya ;

Liu, Mei ;

Walls, Andrew ;

Bousamra, Alex ;

Ramineni, Maheshwari ;

Sinn, Bruno ;

Hunt, Kelly ;

Buchholz, Thomas A. ;

Valero, Vicente ;

Buzdar, Aman U. ;

Yang, Wei ;

Brewster, Abenaa M. ;

Moulder, Stacy ;

Pusztai, Lajos ;

Hatzis, Christos ;

Hortobagyi, Gabriel N. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (10) :1049-+

[47]

The immune microenvironment of breast ductal carcinoma in situ [J].

Thompson, Elizabeth ;

Taube, Janis M. ;

Elwood, Hillary ;

Sharma, Rajni ;

Meeker, Alan ;

Warzecha, Hind Nassar ;

Argani, Pedram ;

Cimino-Mathews, Ashley ;

Emens, Leisha A. .

MODERN PATHOLOGY, 2016, 29 (03) :249-258

[48]

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial [J].

von Minckwitz, Gunter ;

Schneeweiss, Andreas ;

Loibl, Sibylle ;

Salat, Christoph ;

Denkert, Carsten ;

Rezai, Mahdi ;

Blohmer, Jens U. ;

Jackisch, Christian ;

Paepke, Stefan ;

Gerber, Bernd ;

Zahm, Dirk M. ;

Kummel, Sherko ;

Eidtmann, Holger ;

Klare, Peter ;

Huober, Jens ;

Costa, Serban ;

Tesch, Hans ;

Hanusch, Claus ;

Hilfrich, Joern ;

Khandan, Fariba ;

Fasching, Peter A. ;

Sinn, Bruno V. ;

Engels, Knut ;

Mehta, Keyur ;

Nekljudova, Valentina ;

Untch, Michael .

LANCET ONCOLOGY, 2014, 15 (07) :747-756

[49]

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes [J].

von Minckwitz, Gunter ;

Untch, Michael ;

Blohmer, Jens-Uwe ;

Costa, Serban D. ;

Eidtmann, Holger ;

Fasching, Peter A. ;

Gerber, Bernd ;

Eiermann, Wolfgang ;

Hilfrich, Joern ;

Huober, Jens ;

Jackisch, Christian ;

Kaufmann, Manfred ;

Konecny, Gottfried E. ;

Denkert, Carsten ;

Nekljudova, Valentina ;

Mehta, Keyur ;

Loibl, Sibylle .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15) :1796-1804

← 1 2 3 4 5 →